Absolute Quantification of C-reactive Protein in Human Plasma Derived from Patients with Epithelial Ovarian Cancer Utilizing Protein Cleavage Isotope Dilution Mass Spectrometry

Overview

Journal J Proteome Res

Publisher American Chemical Society

Specialty Biochemistry

Date 2009 Feb 7

PMID 19196186

Citations 18

Authors

D Keith Williams

David C Muddiman

Affiliations

Soon will be listed here.

Abstract

A method employing protein cleavage isotope dilution mass spectrometry (PC-IDMS) was developed for quantification of C-reactive protein (CRP) in human plasma. This method was completed without the use of immunoaffinity chromatography or size exclusion chromatography, as previous mass spectrometric methods for the quantification of CRP have employed. A total of 110 human plasma samples were analyzed with PC-IDMS via 1-D nanoLC-MS/MS using a 30 min gradient with a triple quadrupole mass spectrometer operated in selective reaction monitoring (SRM) mode. The results from this newly developed method were compared to results generated from an enzyme-linked immunosorbent assay (ELISA) performed by an independent CLIA certified laboratory. The comparison of these results generated an R(2) = 0.9708 which indicates successful quantification of CRP from human plasma utilizing the methodology described herein. Interestingly, the PC-IDMS method provided concentration values that were approximately 10x the concentration reported by the ELISA method, which demonstrated that the method of detection is an important consideration when determining reference ranges of a particular analyte. In addition, data is shown that illustrates that, as epithelial ovarian cancer (EOC) progresses from stage I to stage IV, mean levels of CRP increase.

Citing Articles

A proposal to improve calibration and outlier detection in high-throughput mass spectrometry.

Zabell A, Lytle F, Julian R Clin Mass Spectrom. 2024; 2:25-33.

PMID: 39192841 PMC: 11322755. DOI: 10.1016/j.clinms.2016.12.003.

Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.

Oliynyk O, Barg W, Slifirczyk A, Oliynyk Y, Gurianov V, Rorat M Viruses. 2021; 13(6).

PMID: 34205217 PMC: 8229480. DOI: 10.3390/v13061067.

Evaluation of INSTAND e.V.'s external quality assessment for C-reactive protein and procalcitonin.

Wojtalewicz N, Schellenberg I, Hunfeld K PLoS One. 2019; 14(8):e0221426.

PMID: 31419260 PMC: 6697325. DOI: 10.1371/journal.pone.0221426.

Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease.

Mesaros C, Blair I Clin Proteomics. 2016; 13:20.

PMID: 27713681 PMC: 5050566. DOI: 10.1186/s12014-016-9121-1.

Accuracy and Reproducibility in Quantification of Plasma Protein Concentrations by Mass Spectrometry without the Use of Isotopic Standards.

Kramer G, Woolerton Y, van Straalen J, Vissers J, Dekker N, Langridge J PLoS One. 2015; 10(10):e0140097.

PMID: 26474480 PMC: 4608811. DOI: 10.1371/journal.pone.0140097.

References

Jeppsson J, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T . Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002; 40(1):78-89. DOI: 10.1515/CCLM.2002.016. View

Scopes R . Measurement of protein by spectrophotometry at 205 nm. Anal Biochem. 1974; 59(1):277-82. DOI: 10.1016/0003-2697(74)90034-7. View

Ridker P . Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107(3):363-9. DOI: 10.1161/01.cir.0000053730.47739.3c. View

Kippen A, Cerini F, Vadas L, Stocklin R, Vu L, Offord R . Development of an isotope dilution assay for precise determination of insulin, C-peptide, and proinsulin levels in non-diabetic and type II diabetic individuals with comparison to immunoassay. J Biol Chem. 1997; 272(19):12513-22. DOI: 10.1074/jbc.272.19.12513. View

Armani A, Becker R . The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part I. Am Heart J. 2005; 149(6):971-6. DOI: 10.1016/j.ahj.2004.12.031. View

Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B . Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics. 2004; 4(4):1175-86. DOI: 10.1002/pmic.200300670. View

Anderson L, Hunter C . Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 2005; 5(4):573-88. DOI: 10.1074/mcp.M500331-MCP200. View

Verma S, Szmitko P, Ridker P . C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med. 2005; 2(1):29-36. DOI: 10.1038/ncpcardio0074. View

Hawkridge A, Heublein D, Bergen 3rd H, Cataliotti A, Burnett Jr J, Muddiman D . Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A. 2005; 102(48):17442-7. PMC: 1297688. DOI: 10.1073/pnas.0508782102. View

10.

Pieper R, Su Q, Gatlin C, Huang S, Anderson N, Steiner S . Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics. 2003; 3(4):422-32. DOI: 10.1002/pmic.200390057. View

11.

Barnidge D, Goodmanson M, Klee G, Muddiman D . Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res. 2004; 3(3):644-52. DOI: 10.1021/pr049963d. View

12.

Barnidge D, Dratz E, Martin T, Bonilla L, Moran L, Lindall A . Absolute quantification of the G protein-coupled receptor rhodopsin by LC/MS/MS using proteolysis product peptides and synthetic peptide standards. Anal Chem. 2003; 75(3):445-51. DOI: 10.1021/ac026154+. View

13.

Maggiore U, Cristol J, Canaud B, Dupuy A, Formica M, Pozzato M . Comparison of 3 automated assays for C-reactive protein in end-stage renal disease: clinical and epidemiological implications. J Lab Clin Med. 2005; 145(6):305-8. DOI: 10.1016/j.lab.2005.03.002. View

14.

Apple F, Maturen A, Mullins R, Painter P, Webster R, Spray Flores J . Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem. 1999; 45(2):206-12. View

15.

Christenson R, Apple F, Morgan D, Alonsozana G, Mascotti K, Olson M . Cardiac troponin I measurement with the ACCESS immunoassay system: analytical and clinical performance characteristics. Clin Chem. 1998; 44(1):52-60. View

16.

Rifai N, Ridker P . High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001; 47(3):403-11. View

17.

Kirkpatrick D, Gerber S, Gygi S . The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods. 2005; 35(3):265-73. DOI: 10.1016/j.ymeth.2004.08.018. View

18.

Barr J, Maggio V, Patterson Jr D, COOPER G, Henderson L, Turner W . Isotope dilution--mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem. 1996; 42(10):1676-82. View

19.

Kiernan U, Addobbati R, Nedelkov D, Nelson R . Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J Proteome Res. 2006; 5(7):1682-7. DOI: 10.1021/pr0601133. View

20.

Anderson L . Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol. 2004; 563(Pt 1):23-60. PMC: 1665562. DOI: 10.1113/jphysiol.2004.080473. View